Countdown to Ninth CIIE Enters Final 100 Days as Participants Grow PresenceYicai·17 hours agoBSX+2.85%SNY+1.50%
Is Sanofi (ENXTPA:SAN) Still Undervalued After Its Eczema Drug Setback?Simplywall·2 days ago, 12:23 AMSNY+1.50%
Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPOGuruFocus·Jul 24 at 01:45 PMSNY+1.50%LLY+0.13%
Sanofi Drops Dupixent Successor Candidate After Assessing Databenzinga_article·Jul 24 at 01:10 PMSNY+1.50%
Sanofi abandons eczema drug approval efforts in another blow to OX40 classPharmaceutical Technology·Jul 24 at 08:20 AMSNY+1.50%
Cardiovascular disease biotech Scribe Therapeutics prices upsized IPO at $15, the high end of the rangeRenaissanceCapital·Jul 24 at 07:21 AMSNY+1.50%LLY+0.13%
SAP Shares Jump After Strong Quarter Reassures Investors of Cloud Business ResilienceMorningStar·Jul 24 at 03:34 AMSAP+6.88%SAP
Sanofi halts atopic dermatitis development of amlitelimab, drops global filing plansPUBT·Jul 24 at 12:30 AMSNY+1.50%
The IPO Buzz: Scribe Therapeutics Upsizes IPO & Prices it at $15 – Top of RangeIPO Scoop·Jul 23 at 10:37 PMSNY+1.50%GS-1.22%
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering | SCTX Stock NewsStockTitan·Jul 23 at 12:08 PMSNY+1.50%
Adocia Notifies Availability of Q2 2026 Financial Results Press ReleasePUBT·Jul 23 at 11:00 AMSNY+1.50%600867+2.86%
Sanofi gets FDA untitled letter over Beyfortus promotional emailsFiercepharma·Jul 22 at 01:49 PMSNY+1.50%
